R

Rekah Pharmaceutical Industry Ltd
TASE:REKA

Watchlist Manager
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Watchlist
Price: 1 300 ILS 3.92%
Updated: May 20, 2024

Rekah Pharmaceutical Industry Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Rekah Pharmaceutical Industry Ltd
Operating Income Peer Comparison

Comparables:
TEVA
TARO
I
INCR
MDWD
C
CSURE

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Operating Income
₪2.9m
CAGR 3-Years
-48%
CAGR 5-Years
-29%
CAGR 10-Years
-17%
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Operating Income
$3.6B
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Taro Pharmaceutical Industries Ltd
NYSE:TARO
Operating Income
$22m
CAGR 3-Years
-49%
CAGR 5-Years
-40%
CAGR 10-Years
-25%
I
InterCure Ltd
TASE:INCR
Operating Income
₪34.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mediwound Ltd
NASDAQ:MDWD
Operating Income
-$15.5m
CAGR 3-Years
-21%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
C
Cannassure Therapeutics Ltd
TASE:CSURE
Operating Income
-₪2.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Rekah Pharmaceutical Industry Ltd's Operating Income?
Operating Income
2.9m ILS

Based on the financial report for Dec 31, 2023, Rekah Pharmaceutical Industry Ltd's Operating Income amounts to 2.9m ILS.

What is Rekah Pharmaceutical Industry Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-17%

Over the last year, the Operating Income growth was -78%. The average annual Operating Income growth rates for Rekah Pharmaceutical Industry Ltd have been -48% over the past three years , -29% over the past five years , and -17% over the past ten years .